Forty Seven

Showing 2 posts of 2 posts found.

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Forty Seven springs out of the blocks ahead of IPO

June 7, 2018
Research and Development, Sales and Marketing Forty Seven, biotech, drugs, pharma, pharmaceutical

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …

The Gateway to Local Adoption Series

Latest content